WEKO3
アイテム
Near-infrared Photoimmunotherapy Targeting Pancreatic Cancer With Tissue Factor Antibody
https://repo.qst.go.jp/records/72996
https://repo.qst.go.jp/records/72996527784ba-32a1-40fc-bbf8-334b020a52bf
| Item type | 会議発表用資料 / Presentation(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2018-11-08 | |||||
| タイトル | ||||||
| タイトル | Near-infrared Photoimmunotherapy Targeting Pancreatic Cancer With Tissue Factor Antibody | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
| 資源タイプ | conference object | |||||
| アクセス権 | ||||||
| アクセス権 | metadata only access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
| 著者 |
Ｕ, Ｗｉｎｎ Ａｕｎｇ
× Ｕ, Ｗｉｎｎ Ａｕｎｇ× Tsuji, Atsushi× Sugyo, Aya× Sudo, Hitomi× Takashima, Hiroki× Yasunaga, Masahiro× Matsumura, Yasuhiro× Higashi, Tatsuya× Ｕ Ｗｉｎｎ Ａｕｎｇ× 辻 厚至× 須尭 綾× 須藤 仁美× 東 達也 |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Purpose: Tissue Factor (TF) is a transmembrane protein and its overexpression is associated with increased tumor growth, tumor angiogenesis and metastatic potential in many malignancies, including pancreatic cancer. Near infrared photoimmunotherapy (NIR-PIT) is a new target-cell-specific cancer treatment that enables highly selective cell death after systemic administration of a photosensitizer-antibody conjugate followed by subsequent NIR light exposure. In this study, we describe the photoimmunotherapeutic effect induced by a rat IgG2b anti-TF monoclonal antibody (anti-TF mAb), conjugated to the photosensitizer, Indocyanine green (ICG), in a TF-expressing BxPC-3 pancreatic cancer model. Materials and methods: Specific binding of the anti-TF-ICG antibody to the TF-expressing BxPC-3 pancreatic cancer cell line was examined by fluorescence microscopy. NIR-PIT-induced cell death was determined by using cell viability imaging assay after exposure of the cells to NIR light. Anti-TF-ICG antibody accumulation in xenograft tumor was acquired in in vivo longitudinal fluorescence imaging. To conduct NIR-PIT, tumor-bearing mice were separated into 5 groups: (1) 100 μg of anti- TF-ICG i.v. administration followed by NIR light exposure (50 J/cm2) for two consecutive days (Day 1 and 2); (2) NIR light exposure (50 J/cm2) only for two consecutive days (Day 1 and 2); (3) 100 μg of anti-TF-ICG i.v. administration; (4) 100 μg of unlabeled anti-TF i.v. administration; (5) the untreated control. Biweekly tumor volume measurements, histopathological and immunohistochemical (IHC) analyses of tumors at 3 days post-administration of anti-TF-ICG antibody were performed to monitor the effect of treatments. Results: Dead cells were obviously seen with cell viability imaging assay. Tumor growth was significantly inhibited by NIR-PIT compared with the other control groups (P < 0.01) for 27 days. Tumors received NIR-PIT showed the evidence of necrotic cell death associated features on H&E staining and decreased cell proliferation marker Ki-67-positive cells on IHC examination. Conclusion: The anti-TF-ICG antibody is suitable as a photosensitizer-antibody conjugate for NIR-PIT. Furthermore, NIR-PIT with the anti-TF-ICG antibody conjugate promises to open a new avenue for treatment of TF-expressing pancreatic cancer and that could be ultimately applicable in clinical use. | |||||
| 会議概要（会議名, 開催地, 会期, 主催者等） | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | Annual Congress of the European Association of Nuclear Medicine 2018 | |||||
| 発表年月日 | ||||||
| 日付 | 2018-10-13 | |||||
| 日付タイプ | Issued | |||||
